File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Relationship between hepatocellular carcinoma development and serum viral markers in patients with undetectable serum HBV DNA level while on nucleos(t)ide analogues

TitleRelationship between hepatocellular carcinoma development and serum viral markers in patients with undetectable serum HBV DNA level while on nucleos(t)ide analogues
Authors
KeywordsMedical sciences - Oncology
Medical sciences - Urology and nephrology
Issue Date2015
PublisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487
Citation
The 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015), Osaka, Japan, 3-5 July 2015. In Liver Cancer, 2015, v. 4 suppl. 1, p. 162, abstract no. O4-1 How to Cite?
AbstractBACKGROUND & AIMS: Hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) are risk factors for hepatocellular carcinoma (HCC) development. Linearized HBsAg kit (Lumipulse G HBsAg-Quant) is a novel assay allowing better quantification of HBsAg level. However, little is known whether they remain important for HCC development if there is profound suppression of viral replication by nucleos(t)ide analogues (NA). METHODS: Seventy-six HBV carriers who developed HCC despite undetectable serum HBV DNA (<20 IU/ml) after at least one-year NA therapy were compared with 152 matched controls who did not have HCC. Clinical and laboratory parameters were analysed in a cross-sectional manner. RESULTS: There was a significant difference in the median values of HBcrAg level between the HCC group and non-HCC group (10.2 and 1.7 kU/ml, respectively, p = 0.005), while there were no significant differences in HBsAg levels by conventional HBsAg kit and linearized HBsAg kit (Lumipulse G HBsAg-Quant). A cutoff value of HBcrAg level ≥7.8 kU/ml yielded an area under receiver operating curve (AUROC) of 0.61 (95% CI: 0.54–0.69) with a negative predictive value (NPV) of 77.0%. The odds ratio of HCC development was 3.27 (95% CI: 1.84–5.80). For the subgroup of non-cirrhotic patients, the median values of HBcrAg level of the HCC and non-HCC group were 10.2 and 1.0 kU/ml respectively (p = 0.001). A cutoff value of HBcrAg level ≥7.9 kU/ml yielded an AUROC of 0.70 (95% CI: 0.58–0.81) with a NPV of 80.6%. The odds ratio of HCC development was 5.95 (95% CI: 2.35–15.07). CONCLUSION: A higher HBcrAg level (but not HBsAg level) was associated with an increased risk of HCC development in patients who achieved undetectable serum HBV DNA while on NA therapy..
DescriptionMeeting Theme: Evidence and Consensus on HCC Management
General Session 7 - Clinical Hepatology
This free online access journal suppl. entitled: Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015)
Persistent Identifierhttp://hdl.handle.net/10722/214866
ISSN

 

DC FieldValueLanguage
dc.contributor.authorCheung, KS-
dc.contributor.authorWong, DKH-
dc.contributor.authorSeto, WK-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, MF-
dc.date.accessioned2015-08-21T11:59:36Z-
dc.date.available2015-08-21T11:59:36Z-
dc.date.issued2015-
dc.identifier.citationThe 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015), Osaka, Japan, 3-5 July 2015. In Liver Cancer, 2015, v. 4 suppl. 1, p. 162, abstract no. O4-1-
dc.identifier.issn2235-1795-
dc.identifier.urihttp://hdl.handle.net/10722/214866-
dc.descriptionMeeting Theme: Evidence and Consensus on HCC Management-
dc.descriptionGeneral Session 7 - Clinical Hepatology-
dc.descriptionThis free online access journal suppl. entitled: Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015)-
dc.description.abstractBACKGROUND & AIMS: Hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) are risk factors for hepatocellular carcinoma (HCC) development. Linearized HBsAg kit (Lumipulse G HBsAg-Quant) is a novel assay allowing better quantification of HBsAg level. However, little is known whether they remain important for HCC development if there is profound suppression of viral replication by nucleos(t)ide analogues (NA). METHODS: Seventy-six HBV carriers who developed HCC despite undetectable serum HBV DNA (<20 IU/ml) after at least one-year NA therapy were compared with 152 matched controls who did not have HCC. Clinical and laboratory parameters were analysed in a cross-sectional manner. RESULTS: There was a significant difference in the median values of HBcrAg level between the HCC group and non-HCC group (10.2 and 1.7 kU/ml, respectively, p = 0.005), while there were no significant differences in HBsAg levels by conventional HBsAg kit and linearized HBsAg kit (Lumipulse G HBsAg-Quant). A cutoff value of HBcrAg level ≥7.8 kU/ml yielded an area under receiver operating curve (AUROC) of 0.61 (95% CI: 0.54–0.69) with a negative predictive value (NPV) of 77.0%. The odds ratio of HCC development was 3.27 (95% CI: 1.84–5.80). For the subgroup of non-cirrhotic patients, the median values of HBcrAg level of the HCC and non-HCC group were 10.2 and 1.0 kU/ml respectively (p = 0.001). A cutoff value of HBcrAg level ≥7.9 kU/ml yielded an AUROC of 0.70 (95% CI: 0.58–0.81) with a NPV of 80.6%. The odds ratio of HCC development was 5.95 (95% CI: 2.35–15.07). CONCLUSION: A higher HBcrAg level (but not HBsAg level) was associated with an increased risk of HCC development in patients who achieved undetectable serum HBV DNA while on NA therapy..-
dc.languageeng-
dc.publisherS. Karger AG. The Journal's web site is located at http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=255487-
dc.relation.ispartofLiver Cancer-
dc.rightsLiver Cancer. Copyright © S. Karger AG.-
dc.subjectMedical sciences - Oncology-
dc.subjectMedical sciences - Urology and nephrology-
dc.titleRelationship between hepatocellular carcinoma development and serum viral markers in patients with undetectable serum HBV DNA level while on nucleos(t)ide analogues-
dc.typeConference_Paper-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailSeto, WK: wkseto@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authoritySeto, WK=rp01659-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, MF=rp00479-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1159/000367745-
dc.identifier.hkuros248016-
dc.identifier.volume4-
dc.identifier.issuesuppl. 1-
dc.identifier.spage162, abstract no. O4-1-
dc.identifier.epage162, abstract no. O4-1-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats